| Androgen and Anabolic Therapies in HIV |  | |  | Slide Presentation September 20, 2006 Donald Abrams, MD
|  |
|
|  |
 |
 |
 |
| IM Testosterone and/or Exercise In Eugonadal Men With AIDS Wasting |  |  Download slide |  |
| IM Testosterone and/or Exercise In Eugonadal Men With AIDS Wasting |  |  Download slide |  |
| IM Testosterone Therapy and Resistance Exercise in Hypogonadal HIV+ Men |  |  Download slide |  |
| IM Testosterone Therapy and Resistance Exercise in Hypogonadal HIV+ Men |  |  Download slide |  |
| Efficacy of TTD Patch (6 mg/day) in Treating HIV Hypogonadism/Wasting |  |  Download slide |  |
| Testosterone Replacement and Mood Effects in Men Living With HIV |  |  Download slide |  |
| Testosterone Replacement and Mood Effects in Men Living with HIV |  |  Download slide |  |
| Testosterone Therapy Delivery Systems: Dosing and Administration |  |  Download slide |  |
| Testosterone Enanthate 250mg Administered IM Every 3 Weeks |  |  Download slide |  |
| Normal Secretory Total Serum Testosterone Profiles in Healthy Young and Older Men |  |  Download slide |  |
| Testosterone Transdermal Patch Used on Nonscrotal Skin over 24 Hours |  |  Download slide |  |
| Structural-Potency Relationships of Commonly Used Anabolic-Androgenic Steroids (Animal Models) |  |  Download slide |  |
| Dehydroepiandrosterone and HIV: A Randomized Placebo-Controlled Study |  |  Download slide |  |
| Estimated effects of DHEA on change in Log10 infectious units per million cells (mean and 95% CI) |  |  Download slide |  |
| Contraindications of Testosterone Replacement Therapy in Men |  |  Download slide |  |
|
 |